Resolution Concerning 12 Years of Data Exclusivity for Biosimilars

The members of PILMA signed the following resolution to establish a regulatory pathway for biosimilars with 12 years of data exclusivity, in order to ensure affordable access to new treatments while encouraging labor job creation for the future.

Click here to view the resolution.

“More medicines are in the development pipeline in America than in the rest of the world combined, nearly 3000”

– Source: U.S. FDA, Office of Orphan Product